Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Trading Statement

13 Oct 2010 07:00

RNS Number : 2488U
Omega Diagnostics Group PLC
13 October 2010
 



 

13 October 2010 AIM: ODX 

 

Omega Diagnostics Group Plc

("Omega")

 

Trading Update

 

Omega, the AIM listed medical diagnostics company announces the following trading update for the six months to 30 September 2010 in advance of releasing its interim results on 26 November 2010.

 

Trading remains in line with management expectations with turnover approximately 15% ahead of the comparative period last year at £3.3 million (2009: £2.87 million). Sales of Genarrayt™ systems and Food Detective™ kits have grown strongly.

 

Genarrayt™

Sales of Genarrayt™ kits and instrument packages have increased substantially in the period by approximately 72% to £761k (2009: £443k). A further 22 system installations have occurred during this period in Brazil, Hungary, India, Israel, Italy, Malaysia, Syria, Thailand, Turkey and UAE bringing the total installed base around the world to approximately 80 systems since launch. We are seeing increased traction of reagent sales from these installations. Reagent sales alone were £632k (2009: £376k) in the period and we expect further progress in sales of reagent kits in the second half following this year's new system installations.

 

Food Detective™

Sales of the macroarray-based Food Detective™ have continued to perform well with volume growth particularly in the Middle East and Far East. Overall, sales of 19,225 kits have been achieved in the first half of this year (2009: 14,957 kits) providing revenues of £369k (2009: £348k). Volume growth has outstripped revenue growth due to the supply of bulk components to a customer in China who then assembles the kits locally. Food Detective™ is now available in over 40 countries.

 

The continued growth of both of these products in the second half of the year will be key. The Directors remain confident in the Group's growth prospects and trading remains in line with management expectations. Alongside the Group's organic growth we have continued to investigate acquisition opportunities.

 

 

Further enquiries:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Ian Soanes

Elizabeth Bowman

Walbrook PR Limited

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMMMGGZVGGZM
Date   Source Headline
22nd May 202012:30 pmRNSExercise of Options and TVR
15th May 202011:05 amRNSSecond Price Monitoring Extn
15th May 202011:00 amRNSPrice Monitoring Extension
13th May 20202:00 pmRNSPrice Monitoring Extension
7th May 20208:15 amRNSExercise of Options and TVR
6th May 202011:00 amRNSPrice Monitoring Extension
4th May 202011:00 amRNSExercise of Options and TVR
1st May 20202:30 pmRNSHolding(s) in Company
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:00 pmRNSPrice Monitoring Extension
30th Apr 202012:00 pmRNSExercise of Options and TVR
29th Apr 20205:37 pmRNSHolding(s) in Company
29th Apr 20207:00 amRNSHolding(s) in Company
28th Apr 20205:43 pmRNSHolding(s) in Company
28th Apr 20207:00 amRNSVISITECT® CD4 Advanced Disease - supply agreement
27th Apr 20204:42 pmRNSSecond Price Monitoring Extn
27th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSCE-Mark of COVID-19 ELISA antibody test
24th Apr 202011:00 amRNSPrice Monitoring Extension
20th Apr 20202:05 pmRNSSecond Price Monitoring Extn
20th Apr 20202:00 pmRNSPrice Monitoring Extension
20th Apr 20201:24 pmRNSHolding(s) in Company
20th Apr 20201:23 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 MTA signed with Mologic Ltd
16th Apr 20205:40 pmRNSHolding(s) in Company
16th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20203:06 pmRNSHolding(s) in Company
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:36 pmRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSCOVID-19 Consortium MOU
6th Apr 20209:30 amRNSVISITECT® CD4 Advanced Disease evaluation
6th Apr 20208:34 amRNSHolding(s) in Company
2nd Apr 20207:00 amRNSChinese Approval for Food Detective® test
2nd Apr 20207:00 amRNSTrading Update
24th Jan 20207:00 amRNSGrant of Options under Company EMI Plan
21st Jan 20203:24 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSExercise of Options and Total Voting Rights
17th Jan 202010:30 amRNSNigerian MOH approval for VISITECT CD4 350 test
8th Jan 202012:13 pmRNSHolding(s) in Company
16th Dec 20194:05 pmRNSDirector/PDMR Shareholding
9th Dec 20194:30 pmRNSHolding(s) in Company
2nd Dec 20199:00 amRNSGrant of Share Options
2nd Dec 20197:00 amRNSInterim Results
2nd Dec 20197:00 amRNSNigerian order for VISITECT® CD4
25th Nov 20197:00 amRNSUpdate on Allergy test menu
21st Nov 20197:00 amRNSInvestor results briefing
22nd Oct 201911:39 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.